American Diabetes Association
Browse

Sociodemographic, Clinical, and Psychosocial Predictors of Short- and Long-Term Study Retention in the Diabetes Prevention Program (DPP) Outcomes Study (DPPOS)

Download (688.24 kB)
figure
posted on 2025-06-20, 00:10 authored by Ashley H. Tjaden, Barbara H. Braffett, Nicole M. Butera, Maria Rosario Araneta, Owen Carmichael, Erik J. Groessl, Helen P. Hazuda, Mary A. Hoskin, Uzoma Ibebuogu, Michelle F. Magee, Marjorie Mau, Tamara Stich, Diana Soliman, Amisha Wallia, Marinella Temprosa, Sherita H. Golden

Objective: Success of longitudinal studies depends on retention of participants. We examined characteristics as predictors of retention among participants with prediabetes and type 2 diabetes (T2D) in the Diabetes Prevention Program (DPP) and the follow-up DPP Outcomes Study (DPPOS).

Research Design and Methods: 3234 adults at high risk of T2D joined the DPP (1996-1999, mean age 51±10y). They were randomized to lifestyle, metformin, or placebo intervention, and then followed through 2020. Logistic regression models estimated the association between baseline sociodemographic, clinical and psychosocial characteristics (life events, family functioning, social support) and short-term retention (~3y). Cox proportional hazards models, censoring at death, estimated the association between baseline and time-varying characteristics and time-to-dropout over the entire 20y of follow-up.

Results: Among surviving participants (N=3218), 93% were retained after 3y and 75% of surviving remained engaged over 20y. Younger age was associated with dropout during DPP and over 20y of follow-up. Female sex, non-White race/ethnicity, employment, and lack of baseline depressive symptoms were associated with better long-term retention. Over time, better health state (SF-36) (HR: 0.89 per 0.1pt; CI: 0.83-0.95) was associated with retention. Greater BMI (1.06 per 5kg/m2; CI: 1.00-1.12), more recent life events (1.08; CI: 1.02-1.14) and depressive symptoms (1.11 per 5pts; CI: 1.05-1.18) were associated with reduced retention. Among adults 45-59y at baseline, development of T2D was associated with better retention (0.75; CI: 0.58-0.97).

Conclusions: Twenty-year retention of a racially and geographically diverse cohort with prediabetes is possible. Retention was associated with age, psychosocial factors, T2D development, and BMI.


Funding

Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) under award numbers U01 DK048489, U01 DK048339, U01 DK048377, U01 DK048349, U01 DK048381, U01 DK048468, U01 DK048434, U01 DK048485, U01 DK048375, U01 DK048514, U01 DK048437, U01 DK048413, U01 DK048411, U01 DK048406, U01 DK048380, U01 DK048397, U01 DK048412, U01 DK048404, U01 DK048387, U01 DK048407, U01 DK048443, and U01 DK048400, by providing funding during DPP and DPPOS to the clinical centers and the Coordinating Center for the design and conduct of the study, and collection, management, analysis, and interpretation of the data. Funding was also provided by the National Institute of Child Health and Human Development, the National Institute on Aging, the National Eye Institute, the National Heart Lung and Blood Institute, the National Cancer Institute, the Office of Research on Women’s Health, the National Institute on Minority Health and Health Disparities, the Centers for Disease Control and Prevention, and the American Diabetes Association. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The Southwestern American Indian Centers were supported directly by the NIDDK, including its Intramural Research Program, and the Indian Health Service. The General Clinical Research Center Program, National Center for Research Resources, and the Department of Veterans Affairs supported data collection at many of the clinical centers. Merck KGaA provided medication for DPPOS. DPP/DPPOS have also received donated materials, equipment, or medicines for concomitant conditions from Bristol-Myers Squibb, Parke-Davis, and LifeScan Inc., Health O Meter, Hoechst Marion Roussel, Inc., Merck-Medco Managed Care, Inc., Merck and Co., Nike Sports Marketing, Slim Fast Foods Co., and Quaker Oats Co. McKesson BioService

History

Usage metrics

    Diabetes Care

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC